Premium
Detection and identification of occult HBV in blood donors in T aiwan using a commercial, multiplex, multi‐dye nucleic acid amplification technology screening test
Author(s) -
Lin K. T.,
Chang C. L.,
Tsai M. H.,
Lin K. S.,
Saldanha J.,
Hung C. M.
Publication year - 2014
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/vox.12075
Subject(s) - multiplex , nucleic acid , nucleic acid test , chemistry , microbiology and biotechnology , virology , medicine , biochemistry , biology , pathology , bioinformatics , disease , covid-19 , infectious disease (medical specialty)
Background The ability of a new generation commercial, multiplex, multi‐dye test from R oche, the cobas T aq S creen MPX test, version 2.0, to detect and identify occult HBV infections was evaluated using routine donor samples from K aohsiung Blood Bank, T aiwan. Study Design and Methods A total of 5973 samples were tested by nucleic acid amplification technology ( NAT ); 5898 in pools of six, 66 in pools of less than six and nine samples individually. NAT ‐reactive samples were retested with alternative NAT tests, and follow‐up samples from the donors were tested individually by NAT and for all the HBV serological markers. Results Eight NAT ‐only‐reactive donors were identified, and follow‐up samples were obtained from six of the donors. The results indicated that all eight donors had an occult HBV infection with viral loads <12 IU/ml. Conclusion The cobas ® T aq S creen MPX test, version 2.0, has an advantage over the current Roche blood screening test, the cobas T aq S creen MPX test, for screening donations in countries with a high prevalence of occult HBV infections since the uncertainty associated with identifying samples with very low viremia is removed by the ability of the test to identify the viral target in samples that are reactive with the cobas TaqScreen MPX test, version 2.0.